Rowena Green Matthews | |
---|---|
Born | Rowena Green 1938 (age 85–86) |
Alma mater | University of Michigan |
Known for | Studies of cobalamin and folic acid |
Scientific career | |
Fields | Biochemistry |
Institutions | University of Michigan |
Doctoral advisor | Vincent Massey |
Rowena Green Matthews (born 1938) [1] is the G. Robert Greenberg Distinguished University professor emeritus at the University of Michigan, Ann Arbor. [2] Her research focuses on the role of organic cofactors as partners of enzymes catalyzing difficult biochemical reactions, especially folic acid and cobalamin (vitamin B12). Among other honors, she was elected to the National Academy of Sciences in 2002 and the Institute of Medicine in 2004. [2]
Matthews was born in Cambridge, England, while her father, biochemist David E. Green, was on sabbatical there. [3] : xxi Matthews earned her B.A. in biology summa cum laude from Radcliffe College in 1960. [4] As an undergraduate, and for three years thereafter, she worked with George Wald studying a new intermediate in the bleaching of the visual pigment rhodopsin that temporally coincided with initiation of visual excitation. [5] She then attended graduate school in biophysics at the University of Michigan, with dissertation research in the laboratory of Vincent Massey. She received her Ph.D. in 1969. [6]
After finishing her Ph.D., Matthews remained at the University of Michigan as a postdoctoral fellow in the laboratory of Charles Williams in the department of Biological Chemistry and Assistant Research Scientist in the Biophysics Research Division in 1978. She was promoted to Associate Professor in 1981 became a full professor in 1986, and became the G. Robert Greenberg Distinguished University Professor in 1995. [2] [6] [7] In 2002, she assumed the position of Senior Research Professor and Charter Faculty Member of the Life Sciences Institute. [8] She retired in 2007, assuming professor emeritus status. [6]
She received numerous recognitions and honors during her career, the Repligen award given by the ACS (2001), [9] election to the National Academy of Sciences (2002), [10] the American Academy of Microbiology (2002), [2] the Institute of Medicine (2004), [11] the American Academy of Arts and Sciences (2005), and the American Philosophical Society (2009). [12] [13] She received the William C. Rose Award given by the American Society for Biochemistry and Molecular Biology in 2000 and the Repligen Corporation Award in Chemistry of Biological Processes given by the American Chemical Society in 2001. [2]
She was the Frederick Gowland Hopkins Lecturer at 12th International Conference of Pteridines and Folates in 2001, an honor she particularly appreciated because her father had worked with Hopkins. [3] She serves on the Medical Advisory Board of the Howard Hughes Medical Institute, [14] and has served on the Council of the National Academy of Sciences. [15]
The University of Michigan hosts a professorship honoring Matthews; since 2009 James Bardwell has held the Rowena G. Matthews Collegiate Professorship. [16]
Dr. Matthew's research focused on one-carbon metabolism, with particular emphasis on the enzymes that catalyze the de novo generation of methyl groups: methionine synthase, a B-12 dependent enzyme in humans, and methylenetetrahydrofolate reductase. [17] [18] Her collaboration with geneticist Rima Rozen at McGill University led to the cloning of human methylenetetrahydrofolate reductase and the characterization of the C677T polymorphism associated with hyperhomocysteinemia in humans. [19] [20] The polymorphism can lead to a high amount of homocysteine in the bloodstream. High concentrations of homocysteine in the plasma can increase the risk for cardiovascular diseases and the use of folic acid have been shown to decrease the amounts in humans. [21] In collaboration with Prof. Martha Ludwig they elucidated the first X-ray structure of vitamin B12 bound to a protein, cobalamin-dependent methionine synthase. [20] [22]
Matthews is the eldest daughter of biochemist David E. Green and the aunt of United States Senator Tammy Baldwin. [26]
Methylation, in the chemical sciences, is the addition of a methyl group on a substrate, or the substitution of an atom by a methyl group. Methylation is a form of alkylation, with a methyl group replacing a hydrogen atom. These terms are commonly used in chemistry, biochemistry, soil science, and biology.
Homocysteine or Hcy: is a non-proteinogenic α-amino acid. It is a homologue of the amino acid cysteine, differing by an additional methylene bridge (-CH2-). It is biosynthesized from methionine by the removal of its terminal Cε methyl group. In the body, homocysteine can be recycled into methionine or converted into cysteine with the aid of vitamin B6, B9, and B12.
S-Adenosyl methionine (SAM), also known under the commercial names of SAMe, SAM-e, or AdoMet, is a common cosubstrate involved in methyl group transfers, transsulfuration, and aminopropylation. Although these anabolic reactions occur throughout the body, most SAM is produced and consumed in the liver. More than 40 methyl transfers from SAM are known, to various substrates such as nucleic acids, proteins, lipids and secondary metabolites. It is made from adenosine triphosphate (ATP) and methionine by methionine adenosyltransferase. SAM was first discovered by Giulio Cantoni in 1952.
Homocystinuria (HCU) is an inherited disorder of the metabolism of the amino acid methionine due to a deficiency of cystathionine beta synthase or methionine synthase. It is an inherited autosomal recessive trait, which means a child needs to inherit a copy of the defective gene from both parents to be affected. Symptoms of homocystinuria can also be caused by a deficiency of vitamins B6, B12, or folate.
Methylenetetrahydrofolate reductase (MTHFR) is the rate-limiting enzyme in the methyl cycle, and it is encoded by the MTHFR gene. Methylenetetrahydrofolate reductase catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for homocysteine remethylation to methionine. Natural variation in this gene is common in otherwise healthy people. Although some variants have been reported to influence susceptibility to occlusive vascular disease, neural tube defects, Alzheimer's disease and other forms of dementia, colon cancer, and acute leukemia, findings from small early studies have not been reproduced. Some mutations in this gene are associated with methylenetetrahydrofolate reductase deficiency. Complex I deficiency with recessive spastic paraparesis has also been linked to MTHFR variants. In addition, the aberrant promoter hypermethylation of this gene is associated with male infertility and recurrent spontaneous abortion.
Methionine synthase (MS, MeSe, MTR) is primarily responsible for the regeneration of methionine from homocysteine in most individuals. In humans it is encoded by the MTR gene (5-methyltetrahydrofolate-homocysteine methyltransferase). Methionine synthase forms part of the S-adenosylmethionine (SAMe) biosynthesis and regeneration cycle, and is the enzyme responsible for linking the cycle to one-carbon metabolism via the folate cycle. There are two primary forms of this enzyme, the Vitamin B12 (cobalamin)-dependent (MetH) and independent (MetE) forms, although minimal core methionine synthases that do not fit cleanly into either category have also been described in some anaerobic bacteria. The two dominant forms of the enzymes appear to be evolutionary independent and rely on considerably different chemical mechanisms. Mammals and other higher eukaryotes express only the cobalamin-dependent form. In contrast, the distribution of the two forms in Archaeplastida (plants and algae) is more complex. Plants exclusively possess the cobalamin-independent form, while algae have either one of the two, depending on species. Many different microorganisms express both the cobalamin-dependent and cobalamin-independent forms.
Methylcobalamin (mecobalamin, MeCbl, or MeB12) is a cobalamin, a form of vitamin B12. It differs from cyanocobalamin in that the cyano group at the cobalt is replaced with a methyl group. Methylcobalamin features an octahedral cobalt(III) centre and can be obtained as bright red crystals. From the perspective of coordination chemistry, methylcobalamin is notable as a rare example of a compound that contains metal–alkyl bonds. Nickel–methyl intermediates have been proposed for the final step of methanogenesis.
Hyperhomocysteinemia is a medical condition characterized by an abnormally high level of total homocysteine in the blood, conventionally described as above 15 μmol/L.
Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is a vitamin found in food and used as a dietary supplement. As a supplement it is used to treat vitamin B12 deficiency including pernicious anemia. Other uses include treatment for cyanide poisoning, Leber's optic atrophy, and toxic amblyopia. It is given by injection into a muscle or vein, by pill or sublingually.
5,10-Methylenetetrahydrofolate (N5,N10-Methylenetetrahydrofolate; 5,10-CH2-THF) is cofactor in several biochemical reactions. It exists in nature as the diastereoisomer [6R]-5,10-methylene-THF.
In enzymology, a 5-methyltetrahydropteroyltriglutamate—homocysteine S-methyltransferase is an enzyme that catalyzes the chemical reaction
In enzymology, a thymidylate synthase (FAD) (EC 2.1.1.148) is an enzyme that catalyzes the chemical reaction
[Methionine synthase] reductase, or Methionine synthase reductase, encoded by the gene MTRR, is an enzyme that is responsible for the reduction of methionine synthase inside human body. This enzyme is crucial for maintaining the one carbon metabolism, specifically the folate cycle. The enzyme employs one coenzyme, flavoprotein.
Cyanocobalamin is a form of vitamin B
12 used to treat and prevent vitamin B
12 deficiency except in the presence of cyanide toxicity. The deficiency may occur in pernicious anemia, following surgical removal of the stomach, with fish tapeworm, or due to bowel cancer. It is used by mouth, by injection into a muscle, or as a nasal spray.
Methionine synthase reductase, also known as MSR, is an enzyme that in humans is encoded by the MTRR gene.
Methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 (MTHFD1) is a gene located in humans on chromosome 14 that encodes a protein, C-1-tetrahydrofolate synthase, cytoplasmic also known as C1-THF synthase, with three distinct enzymatic activities.
In molecular biology, the vitamin B12-binding domain is a protein domain which binds to cobalamin. It can bind two different forms of the cobalamin cofactor, with cobalt bonded either to a methyl group (methylcobalamin) or to 5'-deoxyadenosine (adenosylcobalamin). Cobalamin-binding domains are mainly found in two families of enzymes present in animals and prokaryotes, which perform distinct kinds of reactions at the cobalt-carbon bond. Enzymes that require methylcobalamin carry out methyl transfer reactions. Enzymes that require adenosylcobalamin catalyse reactions in which the first step is the cleavage of adenosylcobalamin to form cob(II)alamin and the 5'-deoxyadenosyl radical, and thus act as radical generators. In both types of enzymes the B12-binding domain uses a histidine to bind the cobalt atom of cobalamin cofactors. This histidine is embedded in a DXHXXG sequence, the most conserved primary sequence motif of the domain. Proteins containing the cobalamin-binding domain include:
Cobalamin biosynthesis is the process by which bacteria and archea make cobalamin, vitamin B12. Many steps are involved in converting aminolevulinic acid via uroporphyrinogen III and adenosylcobyric acid to the final forms in which it is used by enzymes in both the producing organisms and other species, including humans who acquire it through their diet.
Martha Ludwig was an American macromolecular crystallographer. She was the J. Lawrence Oncley Distinguished University Professor of Biological Chemistry at the University of Michigan.
Methylenetetrahydrofolate reductase deficiency is the most common genetic cause of elevated serum levels of homocysteine (hyperhomocysteinemia). It is caused by genetic defects in MTHFR, which is an important enzyme in the methyl cycle.